Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Drug Delivery System

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1223496

Cover Image

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1223496

North America Topical Drug Delivery Market - Industry Trends and Forecast to 2030

PUBLISHED:
PAGES: 242 Pages
DELIVERY TIME: Inquiry
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License) - Printable/Downloadable
USD 3500
PDF (Enterprise License) - Printable/Downloadable
USD 4200

Add to Cart

Description

Table of Contents

List of Tables

The North America topical drug delivery market is projected to register a substantial CAGR of 6.8% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation:

North America Topical Drug Delivery Market, Product Type (Drug Delivery Formulations and Drug Delivery Devices), Delivery Techniques (Sonophoresis, Electroporation, Laser Ablation, Iontophoresis, Radio Frequency Ablation, Magnetophoresis, and Others), Type (Cleansing Agents, Protective Agents, Moisturizing Agents, Drying Agents, Anti-Itch Agents, Anti-Inflammatory Agents, Anti-Infective Agents, Keratolytics, and Others), Generation (First Generation Transdermal Delivery Systems, Second Generation Transdermal Delivery Systems and Third Generation Transdermal Delivery Systems), Mode of Purchase (Prescription and Over The Counter), Indication (Dermatological Disorders, Ophthalmic Disorders, Pain Management, Neurosurgical Disorders, Hormonal Therapy, Smoking Cessation and Others), Roue of Administration (Dermal, Ophthalmic, Rectal, Vaginal, Nasal and Others), End User (Hospitals, Speciality Centers, Home Healthcare, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others), Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2030.

Some major factors contributing to the growth of the North America topical drug delivery market are given below:

High prevalence of skin diseases

Rising company activities in developing products

Market Players:

Some key market players in the North America topical drug delivery market are listed below:

CRESCITA THERAPEUTICS INC.

Cipla Inc.

Glenmark

Bausch Health Companies, Inc.

Merck & Co., Inc.

Novartis AG

Bayer AG

Hisamitsu Pharmaceutical Co., Inc.

Pfizer Inc.

Viatris Inc.

NITTO DENKO CORPORATION

LTS Lohmann Therapy Systems AG

Procter & Gamble

ANI Pharmaceuticals, Inc.

Medherant Limited.

Purdue Pharmaceuticals L.P.

AbbVie Inc.

GSK plc.

3M.

Agile Therapeutics

Tapemark

tesa Labtec GmbH

Noven Pharmaceuticals, Inc.

Show more

TABLE OF CONTENTS

1 INTRODUCTION 25

  • 1.1 OBJECTIVES OF THE STUDY 25
  • 1.2 MARKET DEFINITION 25
  • 1.3 OVERVIEW OF NORTH AMERICA TOPICAL DRUG DELIVERY MARKET 25
  • 1.4 CURRENCY AND PRICING 28
  • 1.5 LIMITATIONS 28
  • 1.6 MARKETS COVERED 28

2 MARKET SEGMENTATION 32

  • 2.1 MARKETS COVERED 32
  • 2.2 GEOGRAPHICAL SCOPE 33
  • 2.3 YEARS CONSIDERED FOR THE STUDY 33
  • 2.4 DBMR TRIPOD DATA VALIDATION MODEL 34
  • 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 37
  • 2.6 MULTIVARIATE MODELLING 38
  • 2.7 MARKET END USER COVERAGE GRID 39
  • 2.8 PRODUCT LIFELINE CURVE 40
  • 2.9 DBMR MARKET POSITION GRID 41
  • 2.10 VENDOR SHARE ANALYSIS 42
  • 2.11 SECONDARY SOURCES 43
  • 2.12 ASSUMPTIONS 43

3 EXECUTIVE SUMMARY 44

4 PREMIUM INSIGHTS 47

  • 4.1 PESTEL 48
  • 4.2 PORTER'S FIVE FORCES MODEL 49

5 INDUSTRIAL INSIGHTS 50

6 PIPELINE ANALYSIS 51

7 EPIDEMIOLOGY 53

8 REGULATORY FRAMEWORK 54

9 MARKET OVERVIEW 55

  • 9.1 DRIVERS 57
    • 9.1.1 HIGH PREVALENCE OF SKIN DISEASES 57
    • 9.1.2 RISING COMPANY ACTIVITIES IN DEVELOPING PRODUCTS AND INCREASING PRODUCT LAUNCHES 57
    • 9.1.3 HIGH INCIDENCE OF BURN INJURIES 58
  • 9.2 RESTRAINTS 58
    • 9.2.1 CONTINUOUS IRRITATION ON THE SKIN AND ALLERGIES CAUSED BY TOPICAL DRUGS 58
    • 9.2.2 DISCONTINUED PRODUCT RECALLS IN THE U.S. 59
  • 9.3 OPPORTUNITIES 59
    • 9.3.1 EXTENSIVE R&D ACTIVITIES IN DERMATOLOGY DRUGS 59
    • 9.3.2 INCREASING INVESTMENT IN BIOLOGICS AND BIOSIMILARS 60
  • 9.4 CHALLENGES 60
    • 9.4.1 STRINGENT REGULATION FOR PRODUCT APPROVAL 60
    • 9.4.2 ALTERNATIVE TO TOPICAL DRUGS FOR TREATMENT 61

10 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY PRODUCT 62

  • 10.1 OVERVIEW 63
  • 10.2 DRUG DELIVERY FORMULATIONS 65
    • 10.2.1 SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS 66
      • 10.2.1.1 OINTMENTS 67
      • 10.2.1.2 CREAM 67
      • 10.2.1.3 GELS 67
      • 10.2.1.4 LOTIONS 67
      • 10.2.1.5 PASTES 67
      • 10.2.1.6 FOAM 67
      • 10.2.1.7 OTHERS 67
    • 10.2.2 LIQUID TOPICAL DRUG DELIVERY 67
      • 10.2.2.1 SOLUTIONS 68
      • 10.2.2.2 SUSPENSION 68
      • 10.2.2.3 OTHERS 68
    • 10.2.3 SOLID TOPICAL DRUG DELIVERY FORMULATIONS 68
      • 10.2.3.1 POWDER 69
      • 10.2.3.2 SUPPOSITORIES 69
      • 10.2.3.3 OTHERS 69
  • 10.3 DRUG DELIVERY SYSTEMS 69
    • 10.3.1 TRANSDERMAL PATCHES 70
      • 10.3.1.1 PASSIVE NON-INVASIVE PATCHES 71
        • 10.3.1.1.1 RECTANGULAR 71
        • 10.3.1.1.2 SQUARE 71
        • 10.3.1.1.3 OTHERS 72
    • 10.3.2 RESERVOIR 72
      • 10.3.2.1 NITROGLYCERINE 72
      • 10.3.2.2 OESTRADIOL 72
      • 10.3.2.3 CLONIDINE 72
      • 10.3.2.4 SCOPOLAMINE 72
      • 10.3.2.5 OTHERS 72
    • 10.3.3 MATRIX 72
      • 10.3.3.1 NICOSTOP PATCH 73
      • 10.3.3.2 ANGIDERM PATCH 73
      • 10.3.3.3 OTHERS 73
    • 10.3.4 DRUG IN-ADHESIVE 73
      • 10.3.4.1 MULTI 73
      • 10.3.4.2 SINGLE 74
    • 10.3.5 NEXT GENERATION PATCHES 74
      • 10.3.5.1 DISPOSABLE NFC BIOMARKER PATCHES 74
      • 10.3.5.2 ZP-PTH RAPID DELIVERY PATCH 74
      • 10.3.5.3 OTHERS 74
    • 10.3.6 ACTIVE PATCHES 74
      • 10.3.6.1 MICRONEEDLE PATCH 75
      • 10.3.6.2 FENTANYL TRANSDERMAL PATCH 75
      • 10.3.6.3 GLYCERALTRINITRATE (GTN) TRANSDERMAL PATCH 75
      • 10.3.6.4 OTHERS 75
    • 10.3.7 MINIMALLY INVASIVE PATCHES 75
      • 10.3.7.1 GELATIN METHACRYLOYL MICRONEEDLE PATCH 76
      • 10.3.7.2 UV PATCH 76
      • 10.3.7.3 OTHERS 76
    • 10.3.8 VAPOR PATCHES 76
      • 10.3.8.1 VICKS VAPOR PATCH 77
      • 10.3.8.2 NAZO VAPOR PATCH 77
      • 10.3.8.3 RUNBUGZ VAPOR PATCH 77
      • 10.3.8.4 OTHERS 77
    • 10.3.9 NANOEMULSION GEL 77
      • 10.3.9.1 MICROSPONGES 77
      • 10.3.9.2 OTHERS 77

11 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY DELIVERY TECHNIQUES 78

  • 11.1 OVERVIEW 79
  • 11.2 IONOTOPHORESIS 81
  • 11.3 SONOPHORESIS 82
  • 11.4 LASER ABLATION 82
  • 11.5 RADIO FREQUENCY ABLATION 82
  • 11.6 MAGNETOPHORESIS 83
  • 11.7 ELECTROPORATION 83
  • 11.8 OTHERS 84

12 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY MODE OF PURCHASE 85

  • 12.1 OVERVIEW 86
  • 12.2 OVER THE COUNTER 89
  • 12.3 PRESCRIPTION 89

13 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY INDICATION 90

  • 13.1 OVERVIEW 91
  • 13.2 DERMATOLOGICAL DISORDERS 93
    • 13.2.1 ACNE 94
    • 13.2.2 ECZEMA 94
    • 13.2.3 RINGWORM 95
    • 13.2.4 ICHTHYOSIS 95
    • 13.2.5 WARTS 95
    • 13.2.6 PSORIASIS 95
    • 13.2.7 ATOPIC DERMATITIS 95
    • 13.2.8 PERIORAL DERMATITIS 95
    • 13.2.9 PRESSURE SORES 95
    • 13.2.10 ROSACEA 95
    • 13.2.11 ATHLETE'S FOOT 95
    • 13.2.12 OTHERS 95
  • 13.3 OPHTHALMIC DISORDERS 96
    • 13.3.1 CONJUNCTIVITIS 97
    • 13.3.2 KERATITIS 97
    • 13.3.3 EYE REDNESS 97
    • 13.3.4 GLAUCOMA 97
    • 13.3.5 BLEPHARITIS 97
    • 13.3.6 IRITIS 97
    • 13.3.7 MACULAR EDEMA 97
    • 13.3.8 PUPILLARY DILATION 97
    • 13.3.9 RETINOPATHY 97
    • 13.3.10 STRABISMUS 97
    • 13.3.11 OTHER 98
  • 13.4 PAIN MANAGEMENT 98
  • 13.5 HORMONAL THERAPY 98
  • 13.6 NEUROLOGICAL DISORDERS 98
  • 13.7 SMOKING CESSATION 99
  • 13.8 OTHERS 99

14 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION 100

  • 14.1 OVERVIEW 101
  • 14.2 DERMAL 103
  • 14.3 OPHTHALMIC 104
  • 14.4 RECTAL 104
  • 14.5 VAGINAL 104
  • 14.6 NASAL 105
  • 14.7 OTHERS 105

15 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY TYPE 106

  • 15.1 OVERVIEW 107
  • 15.2 CLEANSING AGENTS 109
  • 15.3 PROTECTIVE AGENTS 110
  • 15.4 MOISTURIZING AGENTS (EMOLLIENTS) 110
  • 15.5 DRYING AGENTS 110
  • 15.6 ANTI-ITCH AGENTS 111
    • 15.6.1 MENTHOL 112
    • 15.6.2 PRAMOXINE 112
    • 15.6.3 DOXEPIN 112
    • 15.6.4 OTHERS 112
  • 15.7 ANTI- INFLAMMATORY AGENTS 112
    • 15.7.1 CORTICOSTEROIDS 113
    • 15.7.2 CHAMOMILE 113
    • 15.7.3 CALENDULA 113
    • 15.7.4 OTHERS 113
  • 15.8 ANTI-INFECTIVE AGENTS 113
    • 15.8.1 TOPICAL ANTIBIOTICS 114
      • 15.8.1.1 CLINDAMYCIN 114
      • 15.8.1.2 ERYTHROMYCIN 115
      • 15.8.1.3 METRONIDAZOLE 115
      • 15.8.1.4 MUPIROCIN 115
      • 15.8.1.5 BACITRACIN 115
      • 15.8.1.6 POLYMYXIN 115
      • 15.8.1.7 OTHERS 115
    • 15.8.2 TOPICAL ANTIFUNGALS 115
      • 15.8.2.1 KETOCONAZOLE 116
      • 15.8.2.2 MICONAZOLE 116
      • 15.8.2.3 ECONAZOLE 116
      • 15.8.2.4 NYSTATIN 116
      • 15.8.2.5 CICLOPIROX 116
      • 15.8.2.6 TOLNAFTATE 116
      • 15.8.2.7 TERBINAFINE 117
      • 15.8.2.8 CLOTRIMAZOLE 117
      • 15.8.2.9 OTHERS 117
    • 15.8.3 NON-ANTIBIOTIC TOPICAL ANTISEPTICS 117
      • 15.8.3.1 IODINE SOLUTIONS 117
      • 15.8.3.2 GENTIAN VIOLET 117
      • 15.8.3.3 ZINC PYRITHIONE 118
      • 15.8.3.4 SILVER PREPARATIONS 118
      • 15.8.3.5 OTHERS 118
  • 15.9 KERATOLYTICS 118
    • 15.9.1 SALICYLIC ACID 119
    • 15.9.2 UREA 119
    • 15.9.3 OTHERS 119
  • 15.10 OTHERS 119

16 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY GENERATION 120

  • 16.1 OVERVIEW 121
  • 16.2 SECOND-GENERATION TRANSDERMAL DELIVERY SYSTEMS 123
  • 16.3 FIRST-GENERATION TRANSDERMAL DELIVERY SYSTEMS 124
  • 16.4 THIRD-GENERATION TRANSDERMAL DELIVERY SYSTEMS 125

17 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY END USER 126

  • 17.1 OVERVIEW 127
  • 17.2 HOME HEALTHCARE 129
  • 17.3 SPECIALTY CENTRES 130
  • 17.4 HOSPITAL 130
  • 17.5 OTHERS 131

18 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL 132

  • 18.1 OVERVIEW 133
  • 18.2 HOSPITAL PHARMACY 135
  • 18.3 RETAIL PHARMACY 136
  • 18.4 ONLINE PHARMACY 136
  • 18.5 OTHERS 137

19 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY COUNTRY 138

  • 19.1 U.S. 156
  • 19.2 CANADA 169
  • 19.3 MEXICO 182

20 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: COMPANY LANDSCAPE 195

  • 20.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 195

21 SWOT ANALYSIS 196

22 COMPANY PROFILE 197

  • 22.1 CRESCITA THERAPEUTICS INC 197
    • 22.1.1 COMPANY SNAPSHOT 197
    • 22.1.2 REVENUE ANALYSIS 197
    • 22.1.3 PRODUCT PORTFOLIO 198
    • 22.1.4 RECENT DEVELOPMENT 198
  • 22.2 GSK PLC. 199
    • 22.2.1 COMPANY SNAPSHOT 199
    • 22.2.2 REVENUE ANALYSIS 199
    • 22.2.3 PRODUCT PORTFOLIO 200
    • 22.2.4 RECENT DEVELOPMENT 200
  • 22.3 AGILE THERAPEUTICS 201
    • 22.3.1 COMPANY SNAPSHOT 201
    • 22.3.2 REVENUE ANALYSIS 201
    • 22.3.3 PRODUCT PORTFOLIO 202
    • 22.3.4 RECENT DEVELOPMENT 202
  • 22.4 PFIZER INC. 203
    • 22.4.1 COMPANY SNAPSHOT 203
    • 22.4.2 REVENUE ANALYSIS 203
    • 22.4.3 PRODUCT PORTFOLIO 204
    • 22.4.4 RECENT DEVELOPMENT 204
  • 22.5 ABBVIE INC. 205
    • 22.5.1 COMPANY SNAPSHOT 205
    • 22.5.2 REVENUE ANALYSIS 205
    • 22.5.3 PRODUCT PORTFOLIO 206
    • 22.5.4 RECENT DEVELOPMENT 206
Show more
  • 22.6 ANI PHARMACEUTICALS, INC. 207
    • 22.6.1 COMPANY SNAPSHOT 207
    • 22.6.2 REVENUE ANALYSIS 207
    • 22.6.3 PRODUCT PORTFOLIO 208
    • 22.6.4 RECENT DEVELOPMENTS 208
  • 22.7 BAUSCH HEALTH COMPANIES INC. 209
    • 22.7.1 COMPANY SNAPSHOT 209
    • 22.7.2 REVENUE ANALYSIS 209
    • 22.7.3 PRODUCT PORTFOLIO 210
    • 22.7.4 RECENT DEVELOPMENT 210
  • 22.8 BAYER AG 211
    • 22.8.1 COMPANY SNAPSHOT 211
    • 22.8.2 REVENUE ANALYSIS 211
    • 22.8.3 PRODUCT PORTFOLIO 212
    • 22.8.4 RECENT DEVELOPMENT 212
  • 22.9 CIPLA INC. 213
    • 22.9.1 COMPANY SNAPSHOT 213
    • 22.9.2 REVENUE ANALYSIS 213
    • 22.9.3 PRODUCT PORTFOLIO 214
    • 22.9.4 RECENT DEVELOPMENTS 214
  • 22.10 GLENMARK 215
    • 22.10.1 COMPANY SNAPSHOT 215
    • 22.10.2 REVENUE ANALYSIS 215
    • 22.10.3 PRODUCT PORTFOLIO 216
    • 22.10.4 RECENT DEVELOPMENT 216
  • 22.11 HISAMITSU PHARMACEUTICAL CO., INC. 217
    • 22.11.1 COMPANY SNAPSHOT 217
    • 22.11.2 PRODUCT PORTFOLIO 217
    • 22.11.3 RECENT DEVELOPMENT 218
  • 22.12 LTS LOHMANN THERAPY SYSTEMS AG 219
    • 22.12.1 COMPANY SNAPSHOT 219
    • 22.12.2 PRODUCT PORTFOLIO 219
    • 22.12.3 RECENT DEVELOPMENT 219
  • 22.13 MEDHERANT LIMITED. 220
    • 22.13.1 COMPANY SNAPSHOT 220
    • 22.13.2 PRODUCT PORTFOLIO 220
    • 22.13.3 RECENT DEVELOPMENT 220
  • 22.14 MERCK & CO., INC. 221
    • 22.14.1 COMPANY SNAPSHOT 221
    • 22.14.2 REVENUE ANALYSIS 221
    • 22.14.3 PRODUCT PORTFOLIO 222
    • 22.14.4 RECENT DEVELOPMENT 222
  • 22.15 3M. 223
    • 22.15.1 COMPANY SNAPSHOT 223
    • 22.15.2 REVENUE ANALYSIS 223
    • 22.15.3 PRODUCT PORTFOLIO 224
    • 22.15.4 RECENT DEVELOPMENT 224
  • 22.16 NITTO DENKO CORPORATION. 225
    • 22.16.1 COMPANY SNAPSHOT 225
    • 22.16.2 REVENUE ANALYSIS 225
    • 22.16.3 PRODUCT PORTFOLIO 226
    • 22.16.4 RECENT DEVELOPMENTS 226
  • 22.17 NOVARTIS AG 227
    • 22.17.1 COMPANY SNAPSHOT 227
    • 22.17.2 REVENUE ANALYSIS 227
    • 22.17.3 PRODUCT PORTFOLIO 228
    • 22.17.4 RECENT DEVELOPMENT 228
  • 22.18 NOVEN PHARMACEUTICALS, INC. 229
    • 22.18.1 COMPANY SNAPSHOT 229
    • 22.18.2 PRODUCT PORTFOLIO 229
    • 22.18.3 RECENT DEVELOPMENT 229
  • 22.19 PROCTER & GAMBLE 230
    • 22.19.1 COMPANY SNAPSHOT 230
    • 22.19.2 REVENUE ANALYSIS 230
    • 22.19.3 PRODUCT PORTFOLIO 231
    • 22.19.4 RECENT DEVELOPMENT 231
  • 22.20 PURDUE PHARMACEUTICALS L.P. 232
    • 22.20.1 COMPANY SNAPSHOT 232
    • 22.20.2 PRODUCT PORTFOLIO 232
    • 22.20.3 RECENT DEVELOPMENT 232
  • 22.21 TAPEMARKTM 233
    • 22.21.1 COMPANY SNAPSHOT 233
    • 22.21.2 PRODUCT PORTFOLIO 233
    • 22.21.3 RECENT DEVELOPMENT 233
  • 22.22 TESA LABTEC GMBH 234
    • 22.22.1 COMPANY SNAPSHOT 234
    • 22.22.2 PRODUCT PORTFOLIO 234
    • 22.22.3 RECENT DEVELOPMENT 234
  • 22.23 VIATRIS INC. 235
    • 22.23.1 COMPANY SNAPSHOT 235
    • 22.23.2 REVENUE ANALYSIS 235
    • 22.23.3 PRODUCT PORTFOLIO 236
    • 22.23.4 RECENT DEVELOPMENT 237

23 QUESTIONNAIRE 238

24 RELATED REPORTS 242

LIST OF TABLES

  • TABLE 1 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, PIPELINE ANALYSIS 51
  • TABLE 2 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 65
  • TABLE 3 NORTH AMERICA DRUG DELIVERY FORMULATIONS IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 66
  • TABLE 4 NORTH AMERICA SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN TOPICAL DRUG DELIVERY MARKET, PRODUCT TYPE, 2021-2030 (USD MILLION) 66
  • TABLE 5 NORTH AMERICA SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN TOPICAL DRUG DELIVERY MARKET, PRODUCT TYPE, 2021-2030 (MILLION UNITS) 67
  • TABLE 6 NORTH AMERICA LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN TOPICAL DRUG DELIVERY MARKET, PRODUCT TYPE, 2021-2030 (USD MILLION) 68
  • TABLE 7 NORTH AMERICA LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN TOPICAL DRUG DELIVERY MARKET, PRODUCT TYPE, 2021-2030 (MILLION UNITS) 68
  • TABLE 8 NORTH AMERICA SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN TOPICAL DRUG DELIVERY MARKET, PRODUCT TYPE, 2021-2030 (USD MILLION) 69
  • TABLE 9 NORTH AMERICA SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN TOPICAL DRUG DELIVERY MARKET, PRODUCT TYPE, 2021-2030 (MILLION UNITS) 69
  • TABLE 10 NORTH AMERICA DRUG DELIVERY SYSTEMS IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 70
  • TABLE 11 NORTH AMERICA DRUG DELIVERY SYSTEMS IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (MILLION UNITS) 70
  • TABLE 12 NORTH AMERICA TRANSDERMAL PATCHES IN TOPICAL DRUG DELIVERY MARKET, PRODUCT TYPE, 2021-2030 (USD MILLION) 71
  • TABLE 13 NORTH AMERICA PASSIVE NON-INVASIVE PATCHES IN TOPICAL DRUG DELIVERY MARKET, PRODUCT TYPE, 2021-2030 (USD MILLION) 71
  • TABLE 14 NORTH AMERICA RESERVOIR IN TOPICAL DRUG DELIVERY MARKET, PRODUCT TYPE, 2021-2030 (USD MILLION) 72
  • TABLE 15 NORTH AMERICA MATRIX IN TOPICAL DRUG DELIVERY MARKET, PRODUCT TYPE, 2021-2030 (USD MILLION) 73
  • TABLE 16 NORTH AMERICA DRUG IN-ADHESIVE IN TOPICAL DRUG DELIVERY MARKET, PRODUCT TYPE, 2021-2030 (USD MILLION) 73
  • TABLE 17 NORTH AMERICA NEXT GENERATION PATCHES IN TOPICAL DRUG DELIVERY MARKET, PRODUCT TYPE, 2021-2030 (USD MILLION) 74
  • TABLE 18 NORTH AMERICA ACTIVE PATCHES IN TOPICAL DRUG DELIVERY MARKET, PRODUCT TYPE, 2021-2030 (USD MILLION) 75
  • TABLE 19 NORTH AMERICA MINIMALLY INVASIVE PATCHES IN TOPICAL DRUG DELIVERY MARKET, PRODUCT TYPE, 2021-2030 (USD MILLION) 76
  • TABLE 20 NORTH AMERICA VAPOR PATCHES IN TOPICAL DRUG DELIVERY MARKET, PRODUCT TYPE, 2021-2030 (USD MILLION) 76
  • TABLE 21 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY DELIVERY TECHNIQUES, 2021-2030 (USD MILLION) 81
  • TABLE 22 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY MODE OF PURCHASE, 2021-2030 (USD MILLION) 88
  • TABLE 23 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY INDICATION, 2021-2030 (USD MILLION) 93
  • TABLE 24 NORTH AMERICA DERMATOLOGICAL DISORDERS IN TOPICAL DRUG DELIVERY MARKET, BY INDICATION, 2021-2030 (USD MILLION) 94
  • TABLE 25 NORTH AMERICA OPHTHALMIC DISORDERS IN TOPICAL DRUG DELIVERY MARKET, BY INDICATION, 2021-2030 (USD MILLION) 96
  • TABLE 26 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 103
  • TABLE 27 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION) 109
  • TABLE 28 NORTH AMERICA ANTI-ITCH AGENTS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION) 111
  • TABLE 29 NORTH AMERICA ANTI-INFLAMMATORY AGENTS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION) 113
  • TABLE 30 NORTH AMERICA ANTI-INFECTIVE AGENTS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION) 114
  • TABLE 31 NORTH AMERICA TOPICAL ANTIBIOTICS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION) 114
  • TABLE 32 NORTH AMERICA TOPICAL ANTIFUNGALS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION) 116
  • TABLE 33 NORTH AMERICA NON-ANTIBIOTIC TOPICAL ANTISEPTICS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION) 117
  • TABLE 34 NORTH AMERICA KERATOLYTICS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION) 118
  • TABLE 35 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY GENERATION, 2021-2030 (USD MILLION) 123
  • TABLE 36 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY END USER, 2021-2030 (USD MILLION) 129
  • TABLE 37 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 135
  • TABLE 38 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 143
  • TABLE 39 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 143
  • TABLE 40 NORTH AMERICA DRUG DELIVERY FORMULATIONS IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 143
  • TABLE 41 NORTH AMERICA SEMI-SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 144
  • TABLE 42 NORTH AMERICA SEMI-SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (MILLION UNITS) 144
  • TABLE 43 NORTH AMERICA LIQUID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 144
  • TABLE 44 NORTH AMERICA LIQUID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (MILLION UNITS) 145
  • TABLE 45 NORTH AMERICA LIQUID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (MILLION UNITS) 145
  • TABLE 46 NORTH AMERICA SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 145
  • TABLE 47 NORTH AMERICA SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (MILLION UNITS) 145
  • TABLE 48 NORTH AMERICA DRUG DELIVERY SYSTEM IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 146
  • TABLE 49 NORTH AMERICA DRUG DELIVERY SYSTEM IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, BY PRODUCT TYPE, 2021-2030 (MILLION UNITS) 146
  • TABLE 50 NORTH AMERICA TRANSDERMAL PATCHES IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 146
  • TABLE 51 NORTH AMERICA PASSIVE NON-INVASIVE PATCHES IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 147
  • TABLE 52 NORTH AMERICA RESERVOIR IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 147
  • TABLE 53 NORTH AMERICA MATRIX IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 147
  • TABLE 54 NORTH AMERICA DRUG-IN-ADHESIVE IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 147
  • TABLE 55 NORTH AMERICA NEXT-GENERATION PATCHES IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 148
  • TABLE 56 NORTH AMERICA ACTIVE PATCHES IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 148
  • TABLE 57 NORTH AMERICA MINIMALLY INVASIVE PATCH IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 148
  • TABLE 58 NORTH AMERICA VAPOR PATCH IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 148
  • TABLE 59 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY DELIVERY TECHNIQUES, 2021-2030 (USD MILLION) 149
  • TABLE 60 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION) 149
  • TABLE 61 NORTH AMERICA ANTI-ITCH AGENTS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION) 150
  • TABLE 62 NORTH AMERICA ANTI-INFLAMMATORY AGENTS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION) 150
  • TABLE 63 NORTH AMERICA ANTI-INFECTIVE AGENTS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION) 150
  • TABLE 64 NORTH AMERICA TOPICAL ANTIBIOTICS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION) 151
  • TABLE 65 NORTH AMERICA TOPICAL ANTIFUNGALS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION) 151
  • TABLE 66 NORTH AMERICA NON-ANTIBIOTIC TOPICAL ANTISEPTICS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION) 152
  • TABLE 67 NORTH AMERICA KERATOLYTICS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION) 152
  • TABLE 68 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY GENERATION, 2021-2030 (USD MILLION) 152
  • TABLE 69 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY MODE OF PURCHASE, 2021-2030 (USD MILLION) 153
  • TABLE 70 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY INDICATION, 2021-2030 (USD MILLION) 153
  • TABLE 71 NORTH AMERICA DERMATOLOGICAL DISORDERS IN TOPICAL DRUG DELIVERY MARKET, BY INDICATION, 2021-2030 (USD MILLION) 153
  • TABLE 72 NORTH AMERICA OPHTHALMIC DISORDERS IN TOPICAL DRUG DELIVERY MARKET, BY INDICATION, 2021-2030 (USD MILLION) 154
  • TABLE 73 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 154
  • TABLE 74 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY END USER, 2021-2030 (USD MILLION) 155
  • TABLE 75 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 155
  • TABLE 76 U.S. TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 156
  • TABLE 77 U.S. DRUG DELIVERY FORMULATIONS IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 156
  • TABLE 78 U.S. SEMI-SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 156
  • TABLE 79 U.S. SEMI-SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (MILLION UNITS) 157
  • TABLE 80 U.S. SEMI-SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP) 157
  • TABLE 81 U.S. LIQUID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 157
  • TABLE 82 U.S. LIQUID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (MILLION UNITS) 158
  • TABLE 83 U.S. LIQUID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP) 158
  • TABLE 84 U.S. SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 158
  • TABLE 85 U.S. SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (MILLION UNITS) 158
  • TABLE 86 U.S. SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP) 159
  • TABLE 87 U.S. DRUG DELIVERY SYSTEM IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 159
  • TABLE 88 U.S. DRUG DELIVERY SYSTEM IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, BY PRODUCT TYPE, 2021-2030 (MILLION UNITS) 159
  • TABLE 89 U.S. DRUG DELIVERY SYSTEM IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP) 159
  • TABLE 90 U.S. TRANSDERMAL PATCHES IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 160
  • TABLE 91 U.S. PASSIVE NON-INVASIVE PATCHES IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 160
  • TABLE 92 U.S. RESERVOIR IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 160
  • TABLE 93 U.S. MATRIX IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 161
  • TABLE 94 U.S. DRUG-IN-ADHESIVE IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 161
  • TABLE 95 U.S. NEXT-GENERATION PATCHES IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 161
  • TABLE 96 U.S. ACTIVE PATCHES IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 161
  • TABLE 97 U.S. MINIMALLY INVASIVE PATCH IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 162
  • TABLE 98 U.S. VAPOR PATCH IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 162
  • TABLE 99 U.S. TOPICAL DRUG DELIVERY MARKET, BY DELIVERY TECHNIQUES, 2021-2030 (USD MILLION) 162
  • TABLE 100 U.S. TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION) 163
  • TABLE 101 U.S. ANTI-ITCH AGENTS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION) 163
  • TABLE 102 U.S. ANTI-INFLAMMATORY AGENTS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION) 163
  • TABLE 103 U.S. ANTI-INFECTIVE AGENTS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION) 164
  • TABLE 104 U.S. TOPICAL ANTIBIOTICS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION) 164
  • TABLE 105 U.S. TOPICAL ANTIFUNGALS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION) 164
  • TABLE 106 U.S. NON-ANTIBIOTIC TOPICAL ANTISEPTICS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION) 165
  • TABLE 107 U.S. KERATOLYTICS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION) 165
  • TABLE 108 U.S. TOPICAL DRUG DELIVERY MARKET, BY GENERATION, 2021-2030 (USD MILLION) 165
  • TABLE 109 U.S. TOPICAL DRUG DELIVERY MARKET, BY MODE OF PURCHASE, 2021-2030 (USD MILLION) 165
  • TABLE 110 U.S. TOPICAL DRUG DELIVERY MARKET, BY INDICATION, 2021-2030 (USD MILLION) 166
  • TABLE 111 U.S. DERMATOLOGICAL DISORDERS IN TOPICAL DRUG DELIVERY MARKET, BY INDICATION, 2021-2030 (USD MILLION) 166
  • TABLE 112 U.S. OPHTHALMIC DISORDERS IN TOPICAL DRUG DELIVERY MARKET, BY INDICATION, 2021-2030 (USD MILLION) 167
  • TABLE 113 U.S. TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 167
  • TABLE 114 U.S. TOPICAL DRUG DELIVERY MARKET, BY END USER, 2021-2030 (USD MILLION) 168
  • TABLE 115 U.S. TOPICAL DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 168
  • TABLE 116 CANADA TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 169
  • TABLE 117 CANADA DRUG DELIVERY FORMULATIONS IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 169
  • TABLE 118 CANADA SEMI-SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 169
  • TABLE 119 CANADA SEMI-SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (MILLION UNITS) 170
  • TABLE 120 CANADA SEMI-SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP) 170
  • TABLE 121 CANADA LIQUID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 170
  • TABLE 122 CANADA LIQUID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (MILLION UNITS) 171
  • TABLE 123 CANADA LIQUID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP) 171
  • TABLE 124 CANADA SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 171
  • TABLE 125 CANADA SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (MILLION UNITS) 171
  • TABLE 126 CANADA SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP) 172
  • TABLE 127 CANADA DRUG DELIVERY SYSTEM IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 172
  • TABLE 128 CANADA DRUG DELIVERY SYSTEM IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, BY PRODUCT TYPE, 2021-2030 (MILLION UNITS) 172
  • TABLE 129 CANADA DRUG DELIVERY SYSTEM IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP) 172
  • TABLE 130 CANADA TRANSDERMAL PATCHES IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 173
  • TABLE 131 CANADA PASSIVE NON-INVASIVE PATCHES IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 173
  • TABLE 132 CANADA RESERVOIR IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 173
  • TABLE 133 CANADA MATRIX IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 174
  • TABLE 134 CANADA DRUG-IN-ADHESIVE IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 174
  • TABLE 135 CANADA NEXT-GENERATION PATCHES IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 174
  • TABLE 136 CANADA ACTIVE PATCHES IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 174
  • TABLE 137 CANADA MINIMALLY INVASIVE PATCH IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 175
  • TABLE 138 CANADA VAPOR PATCH IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 175
  • TABLE 139 CANADA TOPICAL DRUG DELIVERY MARKET, BY DELIVERY TECHNIQUES, 2021-2030 (USD MILLION) 175
  • TABLE 140 CANADA TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION) 176
  • TABLE 141 CANADA ANTI-ITCH AGENTS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION) 176
  • TABLE 142 CANADA ANTI-INFLAMMATORY AGENTS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION) 176
  • TABLE 143 CANADA ANTI-INFECTIVE AGENTS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION) 177
  • TABLE 144 CANADA TOPICAL ANTIBIOTICS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION) 177
  • TABLE 145 CANADA TOPICAL ANTIFUNGALS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION) 177
  • TABLE 146 CANADA NON-ANTIBIOTIC TOPICAL ANTISEPTICS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION) 178
  • TABLE 147 CANADA KERATOLYTICS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION) 178
  • TABLE 148 CANADA TOPICAL DRUG DELIVERY MARKET, BY GENERATION, 2021-2030 (USD MILLION) 178
  • TABLE 149 CANADA TOPICAL DRUG DELIVERY MARKET, BY MODE OF PURCHASE, 2021-2030 (USD MILLION) 179
  • TABLE 150 CANADA TOPICAL DRUG DELIVERY MARKET, BY INDICATION, 2021-2030 (USD MILLION) 179
  • TABLE 151 CANADA DERMATOLOGICAL DISORDERS IN TOPICAL DRUG DELIVERY MARKET, BY INDICATION, 2021-2030 (USD MILLION) 179
  • TABLE 152 CANADA OPHTHALMIC DISORDERS IN TOPICAL DRUG DELIVERY MARKET, BY INDICATION, 2021-2030 (USD MILLION) 180
  • TABLE 153 CANADA TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 180
  • TABLE 154 CANADA TOPICAL DRUG DELIVERY MARKET, BY END USER, 2021-2030 (USD MILLION) 181
  • TABLE 155 CANADA TOPICAL DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 181
  • TABLE 156 MEXICO TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 182
  • TABLE 157 MEXICO DRUG DELIVERY FORMULATIONS IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 182
  • TABLE 158 MEXICO SEMI-SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 182
  • TABLE 159 MEXICO SEMI-SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (MILLION UNITS) 183
  • TABLE 160 MEXICO SEMI-SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP) 183

LIST OF FIGURES

  • FIGURE 1 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: SEGMENTATION 32
  • FIGURE 2 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: DATA TRIANGULATION 34
  • FIGURE 3 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: DROC ANALYSIS 35
  • FIGURE 4 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS 36
  • FIGURE 5 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: COMPANY RESEARCH ANALYSIS 36
  • FIGURE 6 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: INTERVIEW DEMOGRAPHICS 37
  • FIGURE 7 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: MARKET END USER COVERAGE GRID 39
  • FIGURE 8 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: DBMR MARKET POSITION GRID 41
  • FIGURE 9 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: VENDOR SHARE ANALYSIS 42
  • FIGURE 10 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: SEGMENTATION 46
  • FIGURE 11 INCREASED HEALTHCARE SPENDING AND THE RISE IN THE PREVALENCE OF SKIN DISEASES ARE EXPECTED TO DRIVE THE NORTH AMERICA TOPICAL DRUG DELIVERY MARKET IN THE FORECAST PERIOD 47
  • FIGURE 12 DRUG DELIVERY FORMULATIONS ARE EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA TOPICAL DRUG DELIVERY MARKET IN 2023 & 2030 47
  • FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA TOPICAL DRUG DELIVERY MARKET 56
  • FIGURE 14 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY PRODUCT TYPE, 2022 63
  • FIGURE 15 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION) 64
  • FIGURE 16 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY PRODUCT TYPE, CAGR (2023-2030) 64
  • FIGURE 17 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY PRODUCT TYPE, LIFELINE CURVE 65
  • FIGURE 18 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY DELIVERY TECHNIQUES, 2022 79
  • FIGURE 19 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY DELIVERY TECHNIQUES, 2023-2030 (USD MILLION) 80
  • FIGURE 20 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY DELIVERY TECHNIQUES, CAGR (2023-2030) 80
  • FIGURE 21 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY DELIVERY TECHNIQUES, LIFELINE CURVE 81
  • FIGURE 22 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY MODE OF PURCHASE, 2022 86
  • FIGURE 23 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY MODE OF PURCHASE, 2023-2030 (USD MILLION) 87
  • FIGURE 24 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY MODE OF PURCHASE, CAGR (2023-2030) 87
  • FIGURE 25 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY MODE OF PURCHASE, LIFELINE CURVE 88
  • FIGURE 26 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY INDICATION, 2022 91
  • FIGURE 27 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY INDICATION, 2023-2030 (USD MILLION) 92
  • FIGURE 28 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY INDICATION, CAGR (2023-2030) 92
  • FIGURE 29 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY INDICATION, LIFELINE CURVE 93
  • FIGURE 30 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY ROUTE OF ADMINISTRATION, 2022 101
  • FIGURE 31 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION) 102
  • FIGURE 32 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030) 102
  • FIGURE 33 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 103
  • FIGURE 34 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY TYPE, 2022 107
  • FIGURE 35 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY TYPE, 2023-2030 (USD MILLION) 108
  • FIGURE 36 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY TYPE, CAGR (2023-2030) 108
  • FIGURE 37 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY TYPE, LIFELINE CURVE 109
  • FIGURE 38 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY GENERATION, 2022 121
  • FIGURE 39 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY GENERATION, 2023-2030 (USD MILLION) 122
  • FIGURE 40 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY GENERATION, CAGR (2023-2030) 122
  • FIGURE 41 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY GENERATION, LIFELINE CURVE 123
  • FIGURE 42 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY END USER, 2022 127
  • FIGURE 43 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY END USER, 2023-2030 (USD MILLION) 128
  • FIGURE 44 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY END USER, CAGR (2023-2030) 128
  • FIGURE 45 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY END USER, LIFELINE CURVE 129
  • FIGURE 46 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY DISTRIBUTION CHANNEL, 2022 133
  • FIGURE 47 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 134
  • FIGURE 48 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 134
  • FIGURE 49 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 135
  • FIGURE 50 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: SNAPSHOT (2022) 139
  • FIGURE 51 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY COUNTRY (2022) 141
  • FIGURE 52 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY COUNTRY (2023 & 2030) 141
  • FIGURE 53 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY COUNTRY (2022 & 2030) 142
  • FIGURE 54 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: PRODUCT TYPE (2023-2030) 142
  • FIGURE 55 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: COMPANY SHARE 2022 (%) 195
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!